EquityZen Growth Technology Fund LLC - Series 2037
Raised
$915K
Investors
47
Min Invest
$5,005
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2037 is a Delaware-domiciled pooled investment fund managed by EquityZen Advisors, filing under Rule 506(b) and 3(c)(1) exemptions. The fund raised $915K from 47 investors with a $5K minimum investment, filed March 2025. This is part of the EquityZen platform, which operates 1,889 related pre-IPO investment vehicles.
This pre-IPO fund uses the standard 506(b)/3(c)(1) structure typical of retail-accessible private placements, with a $5K minimum positioning it for broad accredited investor participation. The $19.5K average check size and 47-investor count reflect EquityZen's democratized access model for late-stage private company exposure.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
